REG-4basebio Plc: Exercise of Options and Issue of Equity

4BasebioAnnouncement

09/02/2023 07:15

9 February 2023

4basebio plc
(“4basebio” or the "Company")
 

Exercise of Options and Issue of Equity

4basebio plc (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that it has received a notification from an employee
to exercise options over 2,000 ordinary shares (“New Ordinary Shares”) in
the Company at an exercise price of 118 pence per share for total proceeds of
£2,360.

Following this exercise of options, the Company has options outstanding over
710,500 ordinary shares in aggregate, representing approximately 5.77 per
cent. of the Company’s enlarged issued share capital following admission of
the New Ordinary Shares.

Admission to AIM

Application will be made for the New Ordinary Shares to be admitted to trading
on AIM ("Admission"). It is expected that Admission will become effective at
8.00 a.m. on or around 14 February 2023. The New Ordinary Shares will be
issued credited as fully paid and will rank in full for all dividends and
other distributions declared, made or paid after Admission and will otherwise
rank on Admission pari passu in all respects with the existing ordinary
shares.

Total Voting Rights

Following Admission, the total number of ordinary shares in issue will be
12,319,473. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares with voting rights will be
12,319,473. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

For further information please contact:

 4basebio plc                                        +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                   
                                                                         
 Cairn Financial Advisers LLP (Nominated Adviser )   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                              
                                                                         
 finnCap Ltd (Broker)                                +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                         
                                                                         



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved